DE69624657D1 - Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide - Google Patents

Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide

Info

Publication number
DE69624657D1
DE69624657D1 DE69624657T DE69624657T DE69624657D1 DE 69624657 D1 DE69624657 D1 DE 69624657D1 DE 69624657 T DE69624657 T DE 69624657T DE 69624657 T DE69624657 T DE 69624657T DE 69624657 D1 DE69624657 D1 DE 69624657D1
Authority
DE
Germany
Prior art keywords
cyanopyrazolo
pyrimidin
acetamide
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69624657T
Other languages
English (en)
Other versions
DE69624657T2 (de
Inventor
Padmanathan Thurairajah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DE69624657D1 publication Critical patent/DE69624657D1/de
Publication of DE69624657T2 publication Critical patent/DE69624657T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE69624657T 1995-12-01 1996-11-28 Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide Expired - Lifetime DE69624657T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US785995P 1995-12-01 1995-12-01

Publications (2)

Publication Number Publication Date
DE69624657D1 true DE69624657D1 (de) 2002-12-12
DE69624657T2 DE69624657T2 (de) 2003-08-21

Family

ID=21728482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624657T Expired - Lifetime DE69624657T2 (de) 1995-12-01 1996-11-28 Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide

Country Status (25)

Country Link
US (1) US5714607A (de)
EP (1) EP0776898B1 (de)
JP (1) JP4112032B2 (de)
KR (1) KR100439282B1 (de)
CN (1) CN1057525C (de)
AR (1) AR004822A1 (de)
AT (1) ATE227290T1 (de)
AU (1) AU718310B2 (de)
BR (1) BR9605760A (de)
CA (1) CA2191647C (de)
CY (1) CY2440B1 (de)
CZ (1) CZ292253B6 (de)
DE (1) DE69624657T2 (de)
DK (1) DK0776898T3 (de)
ES (1) ES2184844T3 (de)
HU (1) HU226398B1 (de)
IL (1) IL119710A (de)
MX (1) MX9605974A (de)
NO (1) NO307181B1 (de)
NZ (1) NZ299848A (de)
PT (1) PT776898E (de)
RU (1) RU2178415C2 (de)
SK (1) SK281807B6 (de)
TW (1) TW382629B (de)
ZA (1) ZA9610008B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
CN1610682A (zh) * 2000-08-03 2005-04-27 Wyeth公司 扎来普隆多晶型物及其制备方法
EP1526136A1 (de) * 2000-08-03 2005-04-27 Wyeth Polymorphe Formen von Zaleplon und Verfahren zu ihrer Herstellung
AR029780A1 (es) 2000-12-13 2003-07-16 Gador Sa Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida
US20050032818A1 (en) * 2001-06-12 2005-02-10 Entire Interest N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide and crystalline forms of zaleplon
IL159281A0 (en) * 2001-06-12 2004-06-01 Biogal Pharmaceutical Co Ltd Process for the production of n-[3-(3-cyanopyrazolo{1,5-a} pyrimidin-7-yl) phenyl]-n-ethylacetamide (zaleplon)
HUP0402253A3 (en) * 2001-08-01 2005-12-28 Teva Gyogyszergyar Zartkoeruee Process for the purification of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethylacetamide(zaleplon) and the preparation of its novel crystalline forms and pharmaceutical compositions containing the latters
ATE368667T1 (de) * 2002-02-14 2007-08-15 Cilag Ag Verfahren zur herstellung von n-ethyl-n-(3-(3- cyanopyrazolo-(1,5-a)-pyrimidin-7-yl)phenyl)- acetamid
EP1490068A1 (de) * 2002-02-15 2004-12-29 Biogal Gyogyszergyar Rt. Pulverzusammensetzung mit zaleplon mit definierter teilchengrössenverteilung und daraus hergestellte pharmazeutische produkte
PL207322B1 (pl) * 2002-05-14 2010-11-30 Adamed Społka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania zaleplonu
DE112004001615T5 (de) * 2003-09-04 2006-06-14 Cipla Ltd. Zaleplon-Synthese
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CA2553465A1 (en) * 2004-01-14 2005-08-04 Mallinckrodt Inc. Two-phase method for the synthesis of selected pyrazolopyrimidines
HUP0400325A3 (en) * 2004-02-02 2005-11-28 Richter Gedeon Vegyeszet Pure n-[3-(-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethyl-acetamide, process for its preparation and intermediates
AU2005215376B2 (en) 2004-02-18 2011-01-20 Sunovion Pharmaceuticals Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2006070244A2 (en) * 2004-11-22 2006-07-06 Bakulesh Mafatlal Khamar A process for the preparation of zaleplon
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
US7652018B2 (en) * 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
WO2008068600A2 (en) * 2006-12-06 2008-06-12 Orchid Chemicals & Pharmaceuticals Limited An improved process for the preparation of zaleplo
CZ301145B6 (cs) 2008-07-31 2009-11-18 Farmak, A. S. Zpusob prípravy N-(1-benzo[b]thien-2-ylethyl)-N-hydroxymocoviny
CN102816163A (zh) * 2012-08-20 2012-12-12 四川禾邦阳光制药股份有限公司 扎来普隆的新晶型及制备方法
CN112694336B (zh) * 2020-12-29 2021-11-16 哈尔滨工业大学 一种高纯α相氮化硅纤维毡的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281000A (en) * 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4521422A (en) * 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
NZ208554A (en) * 1983-06-23 1987-06-30 American Cyanamid Co (aryl and heteroaryl)-(7-(aryl and heteroaryl)-pyrazolo (1,5-a) pyrimidin-3-yl)-methanone derivatives and pharmaceutical compositions
JPS62270584A (ja) * 1986-04-28 1987-11-24 Yoshitomi Pharmaceut Ind Ltd ４，７−ジヒドロピラゾロ〔１，５−ａ〕ピリミジン誘導体
GB9321162D0 (en) * 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
HU9603275D0 (en) 1997-01-28
CN1057525C (zh) 2000-10-18
NO965084L (no) 1997-06-02
CZ292253B6 (cs) 2003-08-13
CA2191647A1 (en) 1997-06-02
HUP9603275A2 (en) 1997-08-28
JPH09216885A (ja) 1997-08-19
CN1163893A (zh) 1997-11-05
EP0776898A1 (de) 1997-06-04
SK281807B6 (sk) 2001-08-06
AU7409196A (en) 1997-06-05
CZ350596A3 (en) 1997-09-17
CA2191647C (en) 2005-01-25
IL119710A0 (en) 1997-02-18
NO965084D0 (no) 1996-11-28
AU718310B2 (en) 2000-04-13
US5714607A (en) 1998-02-03
TW382629B (en) 2000-02-21
KR970042543A (ko) 1997-07-24
AR004822A1 (es) 1999-03-10
IL119710A (en) 1999-11-30
ES2184844T3 (es) 2003-04-16
DE69624657T2 (de) 2003-08-21
SK153696A3 (en) 1997-11-05
RU2178415C2 (ru) 2002-01-20
JP4112032B2 (ja) 2008-07-02
PT776898E (pt) 2003-02-28
EP0776898B1 (de) 2002-11-06
HU226398B1 (en) 2008-11-28
HUP9603275A3 (en) 1997-10-28
MX9605974A (es) 1998-04-30
ZA9610008B (en) 1998-08-28
DK0776898T3 (da) 2003-02-24
ATE227290T1 (de) 2002-11-15
BR9605760A (pt) 1998-08-25
CY2440B1 (en) 2004-11-12
NZ299848A (en) 1998-09-24
KR100439282B1 (ko) 2004-08-31
NO307181B1 (no) 2000-02-21

Similar Documents

Publication Publication Date Title
DE69624657T2 (de) Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide
DE921133T1 (de) Herstellung von Gummiartikeln
DE3486287T2 (de) Zwischenprodukte zur Herstellung von 1,2,4-Triazolo[1,5-a]pyrimidin-2-sulfonamiden.
DE69727162D1 (de) Herstellung von inulinhaltigen Produkten
DE69905652D1 (de) Direkte Herstellung von Pyrrolo-(3,4-c)pyrrolpigmenten
DE59806703D1 (de) Herstellung von Formteilen
DE69515140D1 (de) Planarisierung in der Herstellung von Anordnungen
DE69624959T2 (de) Herstellung von Pentafluorphenylverbindungen
DE69508074T2 (de) Herstellung von porösen körpern
DE69804513D1 (de) Herstellung von zeolith-l
DE69525518T2 (de) Herstellung von Raketenkammern
DE69507949D1 (de) Herstellung von keramischen formkörpern
ATE224142T1 (de) Herstellung von nudeln
DE69502001T2 (de) Herstellung von uranoxid
DE69502395T2 (de) Herstellung von triarylboran
DE69516467D1 (de) Feste Lösungen von Pyrrolo-(3,4-c)-pyrrolen mit Chinacridonchinonen
DE59812720D1 (de) Verwendung von phytostenol enthaltender wirkstoffmischungen zur herstellung von hypocholesterinämischen mitteln
DE69521513D1 (de) Herstellung von keramischen artikeln
DE69702961D1 (de) Herstellung von 1,1-difluorethan
DE69611546D1 (de) Herstellung von 2,6-dimethylnaphthalin
DE69619812D1 (de) Kontinuierliche herstellung von 1,1-difluorethan
DE69101849D1 (de) Herstellung von Amiden.
DE69112758D1 (de) Herstellung von Aminonitrilen.
DE69707898T2 (de) Herstellung von bromierten indanen
DE59707175D1 (de) Verwendung von wirkstoffmischungen zur herstellung von hypocholesterinämischen mitteln

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

8327 Change in the person/name/address of the patent owner

Owner name: MEDA AB, SOLNA, SE